Houston, Texas, United States · Est. 2004
Alaunos Therapeutics is a clinical-stage cell therapy company developing personalized cancer immunotherapies using engineered T-cell technologies.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Details
Company Overview
—
Mkt Cap
$15.9M
Revenue
$1.1M
Cash
Therapeutic Focus
Recent SEC Filings
Alaunos Therapeutics, Inc. (TCRT) (CIK 0001107421)
Regulatory
Alaunos Therapeutics, Inc. (TCRT) (CIK 0001107421)
Accession: 001-33038
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)